US Patent 9970030 Methods for increasing CAS9-mediated engineering efficiency

Patent 9970030 was granted and assigned to Caribou Biosciences on May, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Caribou Biosciences

Current Assignee

Caribou Biosciences

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

99700300

Patent Inventor Names

Peter Sean Cameron0

Andrew P. May0

Christopher H. Nye0

Megan van Overbeek0

Rachel E. Haurwitz0

Date of Patent

May 15, 2018

Patent Application Number

148367530

Date Filed

August 26, 2015

Patent Citations Received

‌

US Patent 12110545 Methods of assessing nuclease cleavage

‌

US Patent 12084675 Using programmable DNA binding proteins to enhance targeted genome modification

Patent Primary Examiner

Quang Nguyen

Patent abstract

Methods for use with Type II CRISPR-Cas9 systems for increasing Cas9-mediated genome engineering efficiency are disclosed. The methods can be used to decrease the number of off-target nucleic acid double-stranded breaks and/or to enhance homology-directed repair of a cleaved target nucleic acid.